Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa + Bevacizumab + XELOX for First-Line Treatment of MSS/pMMR Colorectal Cancer Liver Metastases
ChiCTR2600130158Phase 4Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Aug 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of retlirafusp alfa in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 cohorts), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Objective Response Rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2600130158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130158.